CD274 and non-small cell lung carcinoma: Companion PD-L1 testing is approved for bladder, breast, cervical, gastric/gastroesophageal cancers, and NSCLC, and has proven useful in predicting the response in NSCLC with promising data emerging in bladder and gastric/gastroesophageal cancers [70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85].